

# A Systematic Review of Literatures: To Identify Non-Cancer Drugs Repurposed for Lung Cancer

Saikat Samadder<sup>1\*</sup>

<sup>1\*</sup> Corresponding author; Department of Pharmacology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-Gu, Seoul, Korea

Tel: +82-2-2228-1746; E-mail: [SaikatSamadder@yuhs.ac](mailto:SaikatSamadder@yuhs.ac); [Saikat.Samadder46@gmail.com](mailto:Saikat.Samadder46@gmail.com)

## Abstract

**Aim:** The aim of this study is to identify literature suggesting drug repurposing based on various medicines found to possess enhanced efficacy against lung cancer in humans based on pre-clinical and retrospective analysis. Often pre-clinical and retrospective study findings may deviate from the results of randomized prospective clinical studies, this study intends to identify the efficacious new drugs against lung cancer in placebo-controlled studies.

**Methods:** A systematic review of literature was performed in PubMed database on 30<sup>th</sup> August 2023 without any fixed timeline with terms related to ‘drug repurposing’ and ‘Lung cancer’. Post screening of literature, the names of non-chemo drugs identified were further searched in [clinicaltrials.gov](https://clinicaltrials.gov) additionally NCT# was searched in google scholar, in-case the trial results were not available in respective source to validate the study findings.

**Results:** In PubMed 513 articles were found, 9% articles mentioned about drugs with potential efficacy against lung cancer in humans. In these 45 articles 61 non-chemo drugs were identified from specific 293 clinical studies. Among these 30 studies for 23 drugs were in advanced clinical stage and 9 non-chemo medicines were identified to have positive results in randomized controlled clinical trials, rest of the drugs failed to attend designated clinical efficacy till-date. Anti-alcoholism, anti-bacterial, anti-emetics, cox-2 inhibitors, and HMG-CoA reductase inhibitor are the drugs that could potentially effective against advanced non-small cell lung cancer.

**Conclusion:** Applying the advanced search methodology to identify drugs repurposed or approved for targeted disease. All these 9 non-chemo were screened under randomized trial and currently only one drug disulfiram was found to enhance survival and response, reduced disease progression, in advanced NSCLC originally indicated for anti-alcoholism.

**Keywords:** Drug repurposing; drug repositioning; lung cancer; clinical trials; randomized controlled trials.

**Introduction:** Drug repurposing and repositioning are two similar terms often used to define the reuse of approved candidate drug for a completely new indication [1, 2]. For example, anti-viral (zidovudine) repurposed for cancer, and treatment of HIV infection, at the same time analgesics (aspirin) for relieving pain, and anti-coagulant are well known as repurposed medicines (3). Drugs such as 5-flourouracil, and doxorubicin hydrochloride could be considered as repositioned or redirected drugs prescribed to treat multiple types of blood cancer [2]. Drug manufacturing companies spend millions of dollars to identify new pathways or mechanisms by performing proof-of-concept based studies that could mitigate a diseased condition in patients different from originally indicated disease is better defined as drug reprofiling or rediscovery [4]. Considering, that each anti-cancer drug cannot be prescribed for a particular type of cancer as drugs are always cancer or stage specific, due to drug resistance a drug may not be capable of reducing tumor burden in populations, these facts create never ending scope of developing the most effective, efficient, and efficacious drug. There are 1248 drugs approved by USFDA, there are more than 270 anti-neoplastic agents dedicated for cancer treatment [5, 6]. Meanwhile, lung cancer is the second most commonly diagnosed cancer in the world after breast cancer. As per GLOBOCAN report of 2020, globally 2.2 million new cases are reported per year and more than 1.7 million deaths occurs yearly due to lung cancer [7].

In real-world settings patients are treated with more than 900 types of non-chemo medicines to reverse diseased conditions such as fluid accumulation, anorexia, cachexia, various infections, nausea, vomiting, pain, organ failure, immunosuppression, and hyperactivation of immune system caused by anti-neoplastic agents or cancer. Therefore, often real-world evidence (RWE) is systematically reviewed with retrospective study design to identify possible disease modifying effects by non-cancer drugs mainly increased overall survival (OS), disease-free survival (DFS) in patients suffering from various comorbidities [1, 2]. The actual prescribed indication does not vary from the original approved indication. This allows an analysts or physicians to rediscover the disease mitigating effect in patients pre-diagnosed with more severe diseases such as cancer [8]. Drugs such as metformin, statins, anti-depressants, and aspirin etc. were found to have disease modifying effects in lung cancer patients found in retrospective observational studies [9, 10]. This results of mechanism of action (MOA) or proof of concept studies are performed to provide evidence for retrospective analysis [11]. However, in prospective or randomized

placebo-controlled trials the result always varies from the retrospective study or pre-clinical studies [12].

The clinical trials are designed to validate the efficacy and/or safety of a non-chemo drug, often fails to demonstrate therapeutic efficacy when prescribed as a single agent, whereas in presence of chemotherapeutic or anti-neoplastic agents a drug often outperforms in patient group treated with only anti-neoplastic drug. This does not hold sufficient ground for regulatory authorities to approve it as repurposed drug unless validated under placebo-controlled trials [13]. Meanwhile, in clinical trials drug-drug interaction, OS, and drug safety are primary focus of randomized prospective studies applying non-chemo medications for new indication such as non-small cell lung cancer (NSCLC) or any other life-threatening diseases. The findings of a study with review of all approved drugs within a specific time-frame found that there was little or no difference in the evidence supporting supplemental and original indicated approvals, as the number and design of pivotal trials supporting supplemental indicated approvals never lacked well-controlled study designs [14]. USFDA drug policy on drug repurposing the 21<sup>st</sup> century cures act of 13<sup>th</sup> December 2016; suggests approval of a drug for cancer, or any other disease based on study design, most rarely RWE is utilized to support the clinical trial with a historical placebo control arm designed by propensity score matched within the study groups. There was huge applause among researchers regarding metformin for treatment of cancer. However, adding metformin to chemotherapy for advanced NSCLC was safe but did not significantly improve clinical outcomes compared to historical phase 3 control group [15]. Recently, the largest phase 3 randomized trial of metformin adjuvant therapy for breast cancer, enrolled 3,649 women with a 5-year follow-up, found no benefit for DFS or OS treated with metformin. Failure to produce clinical efficacy and application of placebo-controlled in trial are not the only reason for disapproval [13]. The failure of a drug in phase trials is also related to two major types of biases produced in retrospective analysis patient selection and time related biases [12].

Based on retrospective analysis with several deficits in study design suggests drug repurposing supported by pre-clinical trials, here it will be further evaluated that the clinical success of non-chemo medicines in randomized double-blinded placebo-controlled trials. The main purpose of this study is to identify the non-chemo drugs suggested to potentiate anti-neoplastic effect in patients with lung cancer. Here it is further validated the clinical study types, phase, its adverse

events, response rate, safety and efficacy results to identify the extent of drug's ability to provide support lung cancer patients at low cost. Including its approval status, and extent of current clinical application are demonstrated here. Lastly, the non-chemo drugs capable of reducing cancer burden reached to clinical trial stage will be identified by pre-clinical or retrospective study type and to understand the clinical success rate contributed by these approach as supporting evidence adopted or encouraged clinical phase trial. Till date there is no study available to suggest most potential non-chemo drug supposed to be repurposed for lung cancer patients based on evidence of clinical trials.

## **Methods:**

**Primary Search strategy:** The preferred reporting items for systematic reviews and meta-analyses (PRISMA 2020) statement for reporting was utilized [16]. PubMed database was searched on 30<sup>th</sup> Aug 2023 with the following terms ((Drug repurposing) OR (drug repositioning)) OR (drug rediscovery) OR (drug redirecting) OR (drug reprofiling) AND (lung cancer)) without any start timeline applied, to identify all the relevant literatures available [2]. Utilizing these terms as search strings can be considered sufficient as these terms accurately identified articles published in the recent past. The articles found in PubMed were excluded or included based on specific criteria, are provided in (**Figure 1**). Primarily, duplicates and non-English, inaccessible articles were excluded. Secondary, exclusion was applied on articles mainly focusing on in-vitro and in-vivo models, in-silico studies, studies on COVID-19, pulmonary hypertension or fibrosis were excluded. Lastly, studies or review articles reporting or suggesting non-chemo drugs for lung cancer based on findings in human clinical trials were included. Chemo drugs already indicated for the treatment of lung cancer were excluded, few originally indicated for infections later used for cancer treatment but not indicated for lung cancer were considered for inclusion. One study on COVID-19 with patients comorbid with lung cancer suggested doxycycline repurposing was included because another pre-clinical study provided strong evidence (**supplementary material**).

**Additional Search Strategy and Results:** The search fetched a total of 513 literatures, 2 articles were found to be duplicates, 2 articles were inaccessible, 1 article was found as non-English. Records screened 508 among these 73 articles were not related to lung cancer, among

these 435 articles were found to contain findings not related to lung cancer. These 435 articles were sought for retrieval and 48 articles on SARS-CoV-2 related were excluded, 342 articles were pre-clinical studies, in-silico drug discovery studies or computational analysis, pulmonary hypertension, asthma, and related reviews or studies not referring to clinical trials were excluded. Remaining, 45 articles or reviews reported various chemo and non-chemotherapeutic agents for lung cancer in humans with strong clinical evidence was suggested (**supplementary Table S1**). In these 45 articles reported 84 different non-chemo drugs were under phase trials for repurposing against various types of lung cancer no published results (**supplementary figure S2**).

In second step each “non-chemo” drug name and disease “lung cancer” as combination were used to search [clinicaltrials.gov](https://clinicaltrials.gov) on or before 31<sup>st</sup> October 2023. There were 23 drugs out of 84 were found with no studies available in [ClinicalTrials.gov](https://clinicaltrials.gov) were excluded (**supplementary table S3**). Total, 61 out of 84 non-chemo drugs were found with or without trial results for repurposing, and remaining 284 trials were identified and included (**supplementary table S4**) for 61 drug candidates were further searched in [clinicaltrials.gov](https://clinicaltrials.gov) for trial identifier and to evaluate the status, and available literatures and the trials specifically designated and designed to validate the therapeutic efficacy in patients with various patients of lung cancer. Often the trials registered in [clinicaltrials.gov](https://clinicaltrials.gov) for non-chemotherapy drugs for lung cancer lacked the study results with published article title (n = 117), irrelevant articles (n=751), and phase-I study result and other reasons (n=35) were excluded. From 47 articles 12 articles and two NCT03861091, NCT00527319 for 14 non-chemo drugs were in phase II/III clinical studies from [clinicaltrials.gov](https://clinicaltrials.gov) were included. The criteria of inclusion and exclusion for articles in [clinicaltrials.gov](https://clinicaltrials.gov) are shown in (**Figure 1**).

Considering insufficient number of articles found, with the trial registration numbers (n=293 NCT#) were further searched in Google Scholar or before 31<sup>st</sup> October 2023 to identify the findings published as abstract in conferences or research studies, in some cases, systematic review, and meta-analysis (n = 1110) reported for a specific non-chemo drug for lung cancer were excluded, only trial identifier available in published article text were considered and included for further review. A total of 89 clinical trial results were found (n=32) abstracts, (n=12) phase-I studies, and (n=16) articles excluded for other reasons mainly NCT# was not available in

the text additional (n=7) articles non-randomized were excluded. Finally, (n=19) research articles contained published study results from randomized blinded or open-label placebo-controlled trials for (n=22) non-chemo were available for inclusion from google scholar, these articles reported only OS, adverse events, safety, and efficacy of 23 non-chemo medicines were finally included from clinicaltrials.gov or google scholar search. Abstracts published for phase-II/III trials were excluded due to risk of reporting bias. There were 7 articles published articles on 6 non-chemo drugs phase-II trials performed in non-randomized open-label trials were excluded from final assessment but trial results are shown in **supplementary table 5**. Total, 28 articles plus 2 trial results obtained directly from (NCT03861091, NCT00527319) clinicaltrials.gov reported about non-chemo drug's (n=23) clinical success or failure in published or unpublished form (**table 1**). The criteria of inclusion and exclusion for articles found in google scholar are shown in (**Figure 1**).

Articles identified as randomized trials were primarily included but based on availability of randomized placebo-controlled trial result irrespective of negative or positive results, the study was included and any other publications related to same drug reported based on non-randomized, open-label, phase-I studies were not included in final analysis or in **table 1**. In-case two studies on same drug with different treatment plan and drug was available then both the studies were presented, reports removed based on strength of design, reporting, and selection biases. Each of the steps to identify literatures was carried twice to ensure reliability of data assessed independently by a first author further confirmed by corresponding author. The non-chemo drugs list, indication, approval year/status, reference from primary search approach that led to phase trial, present status of candidate drug and availability or unavailability of publication for respective drug is presented in tables (**supplementary table 1 & 2**). The numbers of articles, non-chemo drugs, and clinical trials included and excluded are provided within PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources (**PRISMA flow chart 1**).

Three drugs eprenetapopt, romidepsin, and arsenic trioxide were considered for search in clinicaltrials.gov despite being chemotherapeutic agents because the trials started prior to approval for respective oncogenic indications but were excluded from final assessment. All drugs list suggested in various studies obtained from 423 articles is presented in a table with 57

non-chemo to confirm that clinical trials are not available till-date (**supplementary table 6**). Enalapril maleate, and mirtazapine were found from drugs not reported in pre-clinical studies and not referring human subjects were excluded in final assessment but shown in because ongoing clinical trials available (**supplementary table 4**) and for future tracking of clinical results. Hydroxychloroquine, arsenic trioxide, and nelfinavir were studied in non-randomized trials were excluded from final assessment. Lastly, a bias assessment table is provided and performed similar to constable et al. 2022 [17] with assessment scores is provided in (**supplementary table 7**). There are 6 articles duplicates in clinicaltrials.gov and google scholar highlighted in (**supplementary table 8**). Complete list of 89 articles from google scholar and 47 articles from clinicaltrials.gov are listed in (**supplementary table 9 & 10**). There was no scope of performing meta-analysis due to low number of phase II/III trials available for each drugs. This review was not registered due to the study question as its aim was to identify clinical safety, efficacy and adverse events of non-chemo drugs applied concomitantly or post chemo-chemo therapy in lung cancer patients. Articles in clinical benefit section could be considered as final analyses and not the conclusion.

## **Results:**

**Cardioprotective Compounds:** Anti-hyperlipidemia medications such as simvastatin, pravastatin, anti-hypertensive drugs propranolol, and nitroglycerine prescribed for angina were found effective in pre-clinical studies in in-vitro and in-vivo cancer models. These drugs were studied in advanced lung cancer patients. Propranolol plus etodolac (VT-122) combined treatment was considered for cachexia post radiotherapy. Combinatorial usage did not induce sufficient therapeutic benefit in patients with lung cancer in terms of grasping and weight gain [18]. Pravastatin was widely studied in-vitro and was found to block 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase thereby regulating cholesterol biosynthesis in tumor cells. In a phase-III study design with performance status 0-3 of patients randomly assigned, pravastatin did not extend OS or progression free survival (PFS) compared to placebo [19]. Simvastatin combined with gefitinib or afatinib was studied in two separate well-controlled trials suggested that gefitinib and simvastatin together were capable to prolong survival and PFS in advanced NSCLC patients, but similar efficacy was not observed in treatment group of afatinib and simvastatin compared to control group [20, 21]. Anti-angina medication nitroglycerine was

trailed with other chemotherapeutic agents such as carboplatin, bevacizumab, paclitaxel with/without nitroglycerine did not achieve sufficient safety or efficacy compared to placebo [22]. In a study randomly including stage-IV NSCLC brain metastasis patients treated with whole brain radiation therapy and nitroglycerine or WBRT alone found increased PFS and ORR in nitroglycerine group compared to placebo. There was no difference in OS in nitroglycerine treatment group compared to placebo [23]. In meta-analysis of randomized controlled studies and observational studies separately conducted on of lung cancer patients treated with statins found increased OS [24, 25].

**Anti-microbial agents:** There are numerous anti-microbial and anti-parasitic agents available for the treatment of infections. Among those drugs such as thalidomide, itraconazole, minocycline, doxycycline, clarithromycin, arsenic trioxide, was frequently studied in pre-clinical settings. Thalidomide was indicated for treatment of leprosy (erythema nodosum leprosum), later used for the treatment of graft versus host diseases, in 1998 it was approved for multiple myeloma [26]. Arsenic trioxide was previously indicated for the treatment of syphilis, in 1994 it was approved for the treatment of acute promyelocytic leukemia [27]. The non-randomized study on arsenic trioxide is not presented here. Clarithromycin was not studied as single agent in clinical trials and was studied in presence of pioglitazone and treosulfan [28]. Clinically thalidomide, minocycline, doxycycline was evaluated under randomized, double-blind, placebo-controlled study design.

In RCT's with thalidomide 724 SCLC patients with thalidomide or placebo were further evaluated and found no significant difference in-terms of OS, and quality of life among groups [29]. In second study including advanced NSCLC patients were treated concomitantly with paclitaxel, carboplatin and 60 Gy radiation and thalidomide or placebo. There was no difference in OS, PFS, and ORR among two groups. Incidence of grade 3 or 4 adverse events were higher in thalidomide group compared to placebo [30]. Itraconazole was evaluated under randomized open-label placebo-controlled trial including chemo naïve advanced NSCLC patients treated with platinum-based chemo plus itraconazole regularly for 21 days or placebo. There was significant ORR, and PFS among groups but no difference in 1-year OS [31]. Anti-bacterial medications such as minocycline and doxycycline were found to be inhibit metalloproteinase and vascular endothelial growth factor (VEGF) reducing angiogenesis and degradation of



extracellular matrix (ECM) [32, 33, 34]. In a randomized clinical study advanced NSCLC patients treated with erlotinib with delayed or early minocycline or placebo found early minocycline exposure reduced severe incidence of rash compared to delayed exposure patients with no significant difference in OS [35]. In another study post-chemo therapy with minocycline or alone successfully reduced grade 3 adverse events in minocycline group compared to placebo [36]. Post-dacomitinib treatment of advanced NSCLC patients randomly received doxycycline or placebo and found to significantly reduce the dermatological events and increased quality of life in doxycycline treatment group compared to placebo [37]. In an open-label RCT erlotinib alone or doxycycline combined reduced severity of folliculitis in doxycycline arm compared to control group patients [38]. In an RCT post chemotherapy carboxyaminoimidazole or placebo was applied on patients to evaluate the efficacy and safety found that no significant difference in OS or disease progression observed between groups, significantly lesser adverse events observed in placebo arm [39].

**Immunosuppressive drugs:** There are 6 known anti-inflammatory drugs were tested in lung cancer patients, such as aspirin, celecoxib, apricoxib, Rofecoxib, etodolac and 13-cis-retinoic acid. The drug 13-cis-retinoic acid indicated for acne and all-trans retinoic acid is approved for acute promyelocytic leukemia. Randomly selected lung cancer patients treated with 13 cis retinoic acid with or without tocopherol found no significant change observed in positive histological changes compared to placebo patients [40]. In a randomized double-blinded study aspirin was prescribed to current heavy smokers previously diagnosed with lung cancer, grouped as per dosing continuously or intermittently (one week aspirin and one week placebo). Low dose (81mg) aspirin did not prevent carcinogenesis and incidence of adverse events were similar in both arms [41]. In another study on patients with solid nodules of lungs randomized to receive aspirin or placebo found that there was no significant negative change in the size of the tumors in patients of the treatment group compare to placebo [42]. In 4 different randomized placebo-controlled trials focusing on safety and efficacy of rofecoxib, celecoxib, and apricoxib prescribed along with chemo or immune-therapy regimens found that none of the three anti-inflammatory agents improved OS, rofecoxib and apricoxib improved PFS but celecoxib did not improve PFS in patients compared to placebo [43, 44, 45, 46]. Etodolac and propranolol was combined as (VT-122) was prescribed for cachexia in patients undergoing surgery for lung cancer. After 1

month of therapy with VT-122 no major change in body mass or griping strength, 25% severe adverse events seen in treatment groups [47].

**Anti-diabetic drugs:** Anti-diabetic drugs such as metformin was extensively studied in various cancer patients including in advanced NSCLC patients. There are numerous retrospective and prospective studies suggesting clinical benefits such as prolong OS and PFS in lung cancer patients in absence of diabetes. There are very few randomized double-blind placebo-controlled trial with primary focus on NSCLC patients treated with chemotherapy plus metformin or placebo. One such study performed and could not find beneficial effect in patients treated with metformin and gefitinib in terms of OS/PFS or diarrhea compared to placebo [48]. Pioglitazone another well-known anti-diabetic drug prescribed for type-2 diabetes mellitus was studied for clinical efficacy in high-risk lung cancer patients in randomized double-blind placebo-controlled settings with current or former smokers. The results suggested no improvement of bronchial dysplasia in current smoker with minute benefits in former smokers [49]. In another study NSCLC patients failed treatment with platinum-based chemo regimen were included in the study and received treosulfan, pioglitazone, and clarithromycin daily or nivolumab alone. OS of 9.4 months was seen in pioglitazone plus clarithromycin group compared to 6.9 months in nivolumab group, 75% patients in non-nivolumab group required rescue therapy with immunotherapy [28].

**Anti-resorptive drugs:** Drugs prescribed for osteoporosis patients such as denosumab, bisphosphonates zoledronic acid, and risedronate [50]. Regular intake of anti-osteoporotic medications post-chemotherapeutic intervention reduced depletion of calcium, commonly seen in patients with metastasis to bone. In a study both denosumab and zoledronic acid induced osteonecrosis of the jaw in patients with 40% lung cancer within the study, hypocalcemia was frequently observed in denosumab arm, while acute kidney related adverse events were seen in zoledronic acid patients. In this study bone related events were more frequent in denosumab group than zoledronic acid treated patients [51]. Similar result was obtained in a study analyzed two randomized trials simultaneously with 740 NSCLC patients treated with chemo plus denosumab and chemo alone. This study reported no significant improvement of OS/PFS in patients receiving denosumab compared to control [52]. On the other hand, study including 773 NSCLC patients treated with zoledronic acid 4 mg regular dosing of zoledronic acid for 21

months or placebo resulted in significant reduction of skeletal adverse events [53]. Although, there is no comparative study available on zoledronic acid Vs risedronate in clinical settings. Interestingly, risedronate potentially decreased bone loss in lung cancer patients compared to placebo group and no serious adverse events occurred in patients of treatment group [54]. Reduced skeletal adverse events could be inferred as reduced disease progression resulting in increased OS but this depends on the frequency, age, gender of patients receiving chemotherapy and/or radiotherapy for advanced stage NSCLC. However, zoledronic acid could not increase OS/PFS, progression of metastasis and impaired renal function in patients treated with zoledronic acid [55].

**Anti-alcoholic agent:** There are multiple anti-addiction drugs are available in the market. Among all disulfiram was intensively studied in-vitro and in-vivo cancer models. Disulfiram a metallodrug primary known for inhibiting cellular aldehyde dehydrogenases, it forms copper diethyldithiocarbamate complex ( $\text{Cu}(\text{DDC})_2$  complex) that induces redox reaction by forming  $\text{Cu}(\text{DDC})_2$  resulting in ROS generation causing tumor cell death [56]. Disulfiram is one of the few drugs capable of inducing apoptosis in cancer stem cells by suppressing nuclear factor kappa-light-chain-enhancer of activated B cells (NF $\kappa$ B) pathway [57]. Selective and effective killing of cancer stem cells was linked to increased OS and PFS in advanced NSCLC patients. In multicenter, randomized, double-blinded placebo-controlled study treated advanced NSCLC patients with cisplatin, vinorelbine and disulfiram or no disulfiram, found 10 months OS, and 5.9 months PFS compared to untreated patients survived 7.1 and 4.9 months of PFS. Disulfiram being a regularly prescribed medication for alcoholism has very little-known adverse events caused clinically in patients, further clinical studies demonstrating safety in terms of serious adverse events should be the focus in future [58].

**Neuromodulatory drugs:** Desipramine, and valproic acid are currently completed phase-II trials, more studies are required because present studies are open-label single arm studies. Neurokin-1 inhibitor aprepitant completed phase-III trial and was found to achieve desired activity in patients. Aprepitant was prescribed alone or with palonosetron and dexamethasone with or without post-chemo, addition of aprepitant to patient group significantly reduced vomiting but not nausea compared to unexposed patients. Based on these and other advanced

study results aprepitant is currently as an approved anti-emetic for chemotherapy-induced nausea and vomiting for cancer patients [59].

**Limitations:** The reliability of clinical studies are partially affected due to open-label status that determines the strength of a trial in-terms of biases. Trials those are randomized, double-blind, placebo-controlled design are considered highest standard for identifying drug safety and efficacy. Phase II/III trials recruiting only advanced stage patients accurately generates the clinical end-point results. Evaluation based on compliance in reporting with statistical analyses are efficient in reducing reporting biases. Based on these important facts the drugs found to have potential efficacy and safety such as simvastatin, itraconazole, minocycline, doxycycline, and disulfiram were found beneficial for patients, at the same time these trials contained least overall biases. Minocycline and doxycycline studies were both open and blinded therefore has moderate biases and results are reliable, simvastatin, and itraconazole studies were open label this slightly increases the risk of biases. 13 Out of 30 (50%) studies were performed in randomized double-blind placebo-controlled clinical set-up suggested for non-chemo drug repurposing in advanced NSCLC. The study on disulfiram was a phase-IIb study with very low number of patients, further study is necessary recruiting a larger number of patients. Rofecoxib, apricoxib, celecoxib, simvastatin, itraconazole, and disulfiram including one study related of doxycycline treated patients concomitantly with chemo. Post-chemotherapy drug exposure was found in one study of doxycycline, and two studies of minocycline. The treatment plan were aligned to effectively identify clinical end-points, further reduced reporting bias. Among all 30 randomized trials, the 15 phase-II/III studies with clinical endpoint success are discussed in clinical benefit section as all these recruited a specific type of lung cancer patients, further reducing design, and selection biases. All the trials included in final assessment of this study are related to rofecoxib, apricoxib, celecoxib, simvastatin, itraconazole, minocycline, doxycycline, and disulfiram consisted of low-moderate biases in-terms of study design, patients selection, and reporting. Remaining 15 studies were open label, studies on aspirin lacked placebo arm, two studies on risedronate and VT-122 were unpublished and may contribute to reporting biases. Long term prescribed drugs such as simvastatin or metformin, the accumulated trials consisted of patients non-comorbid with hyperglycemia or hyperlipidemia this reduced selectivity biases. The articles obtained from each searches were eventually excluded are shown in supplementary table thereby reducing biases of

this study. COCHRANE database was not searched thereby limiting the studies registered in other geographical locations.

**Clinical Benefits:** The primary aim of each of the RCTs was to identify the non-chemo drug's ability to measure the potentiality of enhancing OS, PFS, and inducing overall response rate (ORR) in advanced NSCLC patients and the trials with high grade study design can effectively suggest drug repurposing are presented in this study. Non-chemo medications such as pravastatin, propranolol, aspirin, etodolac, 13-cis retinoic acid, metformin, pioglitazone, thalidomide, clarithromycin, carboxyaminoimidazole, denosumab, could not achieve desired clinical end-points in the registered trials [18, 19, 28, 29, 30, 39, 40, 41, 42, 48, 49, 53, 54]. Etodolac may not be beneficial for lung cancer but was found effective against colorectal and breast cancer [60, 61]. Similarly, metformin may have more beneficial effect in other cancer than in lung cancer patients. Rofecoxib was found associated with cardiac event in cancer patients compared to placebo patients [62]. Nitroglycerine increased the risk of post-exposure headache in NSCLC patients [22]. Non-chemo such as itraconazole, apricoxib, and rofecoxib could potentially improve ORR and reduce disease progression in patients with NSCLC [31, 45, 46]. Disulfiram along with cisplatin, and vinorelbine was effective in extending survival, response rate, and reduced disease progression in advanced NSCLC patients at the same time simvastatin, and gefitinib in combination would provide similar benefits in advanced stage NSCLC patients [20, 58]. Based on clinical efficacy results of disulfiram in large group of NSCLC patients, it could be repurposed. So far, the safety is concerned simvastatin, minocycline, doxycycline, itraconazole, aprepitant, zoledronic acid, risedronate and rofecoxib contributed to least incidence of adverse events in advanced NSCLC patients [20, 31, 36, 43, 37, 38, 54, 56, 60]. Based on safety and efficacy aprepitant is already indicated for chemo-therapy induced nausea and vomiting in 2003 but it has no effect on OS/PFS [59]. However, reduced nausea increases quality of life in patients undergone heavy or moderate chemo-radio therapeutic regimens. Only study to demonstrate the effect of non-chemo drug (aspirin) in reduction of tumor size failed to find sufficient reduction in tumor size compared to placebo [42]. In a recent review article, found 14 clinical trials designed to screen lung cancer prevention [63]. Compared to our study in a recent systematic review found 11 non-chemo drugs suggested for various cancer patients [64]. The

approach utilized here to effectively find RCT is beneficial for obtaining maximum pivotal studies.

**Conclusion:** There are more than 150 non-chemo drugs suggested for various cancer treatment [11, 65]. Finding the cheapest drug that could potentially prolong survival in advanced stage patients is of great importance. Currently, none of the non-anti-neoplastic agents are capable of producing tumor killing activity in absence of anti-neoplastic drugs, all the clinical studies presented here were coherent to this well-known treatment plan. In pre-clinical studies single agents produce significant cell deaths of cancerous cell lines, provides sufficient preliminary evidence for further proceeding to in-vivo studies [66]. In retrospective analysis matching concomitant treatment with several other non-chemo drug's effect is not usually reported by performing propensity score matching resulting in biased reporting. Excluding the fact that in patients with a specific symptom received a particular non-chemo increases a selection biases of retrospective studies [12]. These limits the reliability of evidence provided in retrospective studies for drug repurposing, by using machine learning it could be avoided, although statistical significance similar to placebo-controlled phase-III trials may not be achieved to confirm this further study is required [67]. Nelfinavir is a potential drug candidate capable of producing distinct and advanced tumor destruction with minimal adverse events, it increased OS, PFS, and ORR in patients further well-controlled studies are required in larger population to demonstrate efficacy and safety for the drug to be repurposed [68]. All the studies were performed on advanced stage NSCLC patients, other non-chemo drugs studied in extensive SCLC or malignant methelioma were not effective for repurposing. All the non-chemo successfully reducing adverse events, OS/PFS, were identified pre-clinically, supported by retrospective analysis of RWE, leading to randomized prospective studies to further screen the clinical efficacy, later demonstrated in meta-analysis with efficacy in patient population sub-groups [69]. This flow was followed for all of drugs screened for repurposing, drugs identified from retrospective analysis (aspirin/metformin) may perform well, but distinct clinical efficacy reduces in phase trails was absent. The phase-II/III trials evaluating non-chemo drugs safety and efficacy profile could be the only method for screening therapeutic benefits in patients by conducting advanced clinical trials at the same time historical placebo could be effectively used beside prospectively treatment arm [70]. Simvastatin and disulfiram was found to increase overall survival but phase-III studies

are required, recruiting a greater number of patients to obtain distinct clinical benefits. Doxycycline along with bleomycin is prescribed for the management of malignant pleural effusions often reported in patients with various types of lung cancer [71]. Aprepitant significantly reduced several adverse events arising due to chemo/radio therapy such as nausea, pruritus and reduced cough in chemo naïve advanced lung cancer patients [59, 72, 73].

**Acknowledgement:** The author would like to thank Professor Kyungsoo Park (Yonsei University) for the research questions.

**Conflict of interest:** The author does not have any conflict of interests to declare.

**Funding source:** No funding was received for this study.

### Reference:

1. Park K. A review of computational drug repurposing. *Transl Clin Pharmacol*. 2019 Jun;27(2):59-63. doi: 10.12793/tcp.2019.27.2.59.
2. Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. *Drug Discov Today*. 2015 Aug;20(8):1027-34. doi: 10.1016/j.drudis.2015.05.001.
3. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. *Nat Rev Drug Discov*. 2019 Jan;18(1):41-58. doi: 10.1038/nrd.2018.168.
4. Nawaz K, Webster RM. The non-small-cell lung cancer drug market. *Nat Rev Drug Discov*. 2016 Apr;15(4):229-30. doi: 10.1038/nrd.2016.42.
5. Pantziarka P, Capistrano I R, De Potter A, Vandeborne L, Bouche G. An Open Access Database of Licensed Cancer Drugs. *Front Pharmacol*. 2021 Mar 11;12:627574. doi: 10.3389/fphar.2021.627574.
6. CenterWatch A WCG company | FDA Approved Drugs | accessed on Oct 28<sup>th</sup> 2023 | website: <https://www.centerwatch.com/directories/1067-fda-approved-drugs?page=54>
7. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.
8. Zong N, Wen A, Moon S, Fu S, Wang L, Zhao Y, Yu Y, Huang M, Wang Y, Zheng G, Mielke MM, Cerhan JR, Liu H. Computational drug repurposing based on electronic health records: a scoping review. *NPJ Digit Med*. 2022 Jun 14;5(1):77. doi: 10.1038/s41746-022-00617-6.

9. Wu Y, Warner JL, Wang L, Jiang M, Xu J, Chen Q, Nian H, Dai Q, Du X, Yang P, Denny JC, Liu H, Xu H. Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing. *JCO Clin Cancer Inform*. 2019 May;3:1-9. doi: 10.1200/CCI.19.00001.
10. Abdel Karim NF, Hassan R, Siddiqi NI, Eldessouki I, Gaber O, Rahouma M, Kamel M, Yellu M, Gulati S, Xie C, Magdy M, Pruemmer J. Impact of tricyclic antidepressants, selective serotonin reuptake inhibitors, and other antidepressants on overall survival of patients with advanced lung cancer from 2004 to 2014: University of Cincinnati experience. *J Int Med Res*. 2019 Dec;47(12):6016-6026. doi: 10.1177/0300060519862469.
11. Jain AS, Prasad A, Pradeep S, Dharmashekar C, Achar RR, Silina E, Stupin V, Amachawadi RG, Prasad SK, Pruthvish R, Syed A, Shivamallu C, Kollur SP. Corrigendum: Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway. *Front Oncol*. 2021 Dec 20;11:822865. doi: 10.3389/fonc.2021.822865.
12. Yu OHY, Suissa S. Metformin and Cancer: Solutions to a Real-World Evidence Failure. *Diabetes Care*. 2023 May 1;46(5):904-912. doi: 10.2337/dci22-0047.
13. Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. *JAMA*. 2022 May 24;327(20):1963-1973. doi: 10.1001/jama.2022.6147.
14. Dhodapkar M, Zhang AD, Puthumana J, Downing NS, Shah ND, Ross JS. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019. *JAMA Netw Open*. 2021 Jun 1;4(6):e2113224. doi: 10.1001/jamanetworkopen.2021.13224.
15. Parikh AB, Kozuch P, Rohs N, Becker DJ, Levy BP. Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial. *Invest New Drugs*. 2017 Dec;35(6):813-819. doi: 10.1007/s10637-017-0511-7.
16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: <http://www.prisma-statement.org/>
17. Constable C, Ferguson K, Nicholson J, Quinn GP. Clinician communication strategies associated with increased uptake of the human papillomavirus (HPV) vaccine: A systematic review. *CA Cancer J Clin*. 2022 Nov;72(6):561-569. doi: 10.3322/caac.21753.
18. Regimen for the Treatment of Cachexia in Subjects With NSCLC (VT-122). (NCT00527319), ClinicalTrials.gov; January 30, 2013, <https://classic.clinicaltrials.gov/ct2/show/study/NCT00527319>



[00527319?term=NCT00527319&draw=2&rank=1](https://doi.org/10.1101/2023.12.03.23299334) (accessed on October 28, 2023)

19. Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). *J Clin Oncol*. 2017 May 10;35(14):1506-1514. doi: 10.1200/JCO.2016.69.7391.
20. Han JY, Lee SH, Yoo NJ, Hyung LS, Moon YJ, Yun T, Kim HT, Lee JS. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. *Clin Cancer Res*. 2011 Mar 15;17(6):1553-60. doi: 10.1158/1078-0432.CCR-10-2525.
21. Lee Y, Lee KH, Lee GK, Lee SH, Lim KY, Joo J, Go YJ, Lee JS, Han JY. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. *Cancer Res Treat*. 2017 Oct;49(4):1001-1011. doi: 10.4143/crt.2016.546.
22. Dingemans AM, Groen HJ, Herder GJ, Stigt JA, Smit EF, Bahce I, Burgers JA, van den Borne BE, Biesma B, Vincent A, van der Noort V, Aerts JG; NVALT study group. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†. *Ann Oncol*. 2015 Nov;26(11):2286-93. doi: 10.1093/annonc/mdv370.
23. Arrieta O, Hernández-Pedro N, Maldonado F, Ramos-Ramírez M, Yamamoto-Ramos M, López-Macías D, Lozano F, Zatarain-Barrón ZL, Turcott JG, Barrios-Bernal P, Orozco-Morales M, Flores-Estrada D, Cardona AF, Rolfo C, Cacho-Díaz B. Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial. *Int J Radiat Oncol Biol Phys*. 2023 Mar 1;115(3):592-607. doi: 10.1016/j.ijrobp.2022.02.010.
24. Xia DK, Hu ZG, Tian YF, Zeng FJ. Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials. *Drug Des Devel Ther*. 2019 Jan 23;13:405-422. doi: 10.2147/DDDT.S187690.
25. Chen Y, Li X, Zhang R, Xia Y, Shao Z, Mei Z. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. *Pharmacol Res*. 2019 Mar;141:357-365. doi: 10.1016/j.phrs.2019.01.016.
26. Grogan DP, Winston NR. Thalidomide. [Updated 2023 Jun 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557706/>
27. Jiang, Y., Shen, X., Zhi, F. *et al.* An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications. *Cell Death Discov*. 9, 266 (2023). <https://doi.org/10.1038/s41420-023-01558-z>

28. Heudobler D, Schulz C, Fischer JR, Staib P, Wehler T, Südhoff T, Schichtl T, Wilke J, Hahn J, Lüke F, Vogelhuber M, Klobuch S, Pukrop T, Herr W, Held S, Beckers K, Bouche G and Reichle A (2021) A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic LowDose Chemotherapy with SingleAgent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). *Front. Pharmacol.* 12:599598. doi: 10.3389/fphar.2021.599598.
29. Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. *J Natl Cancer Inst.* 2009 Aug 5;101(15):1049-57. doi: 10.1093/jnci/djp200.
30. Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, Johnson DH. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. *J Clin Oncol.* 2012 Feb 20;30(6):616-22. doi: 10.1200/JCO.2011.36.9116.
31. Mohamed AW, Elbassiouny M, Elkhodary DA, Shawki MA, Saad AS. The effect of itraconazole on the clinical outcomes of patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a randomized controlled study. *Med Oncol.* 2021 Feb 9;38(3):23. doi: 10.1007/s12032-021-01475-0.
32. Sasamura, H., Takahashi, A., Miyao, N. *et al.* Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. *Br J Cancer* **86**, 768–773 (2002). <https://doi.org/10.1038/sj.bjc.6600152>
33. Yao JS, Shen F, Young WL, Yang GY. Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. *Neurochem Int.* 2007 Feb;50(3):524-30. doi: 10.1016/j.neuint.2006.10.008.
34. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TS, Copeland J, Petzold G, Mitchell M, Ledbetter S, Poorman R, Wilks JW, Fisher C (1995) The tetracycline analogs minocycline and doxycycline inhibit angiogenesis *in vitro* by a non-metalloproteinase-dependent mechanism. *Cancer Chemother Pharmacol* **36**: 418–424
35. Melosky B, Anderson H, Burkes RL, Chu Q, Hao D, Ho V, Ho C, Lam W, Lee CW, Leigh NB, Murray N, Sun S, Winston R, Laskin JJ. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients with Metastatic Lung Cancer. *J Clin Oncol.* 2016 Mar 10;34(8):810-5. doi: 10.1200/JCO.2015.62.3918.
36. Wang XS, Shi Q, Mendoza T, Lin S, Chang JY, Bokhari RH, Lin HK, Garcia-Gonzalez A, Kamal M, Cleeland CS, Liao Z. Minocycline Reduces Chemoradiation-Related Symptom

- Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. *Int J Radiat Oncol Biol Phys*. 2020 Jan 1;106(1):100-107. doi: 10.1016/j.ijrobp.2019.10.010.
37. Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, Doherty JP, Giri N, Nadanaciva S, O'Connell J, Sbar E, Piperdi B, Garon EB. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. *Ann Oncol*. 2016 Sep;27(9):1712-8. doi: 10.1093/annonc/mdw227.
  38. Deplanque G, Gervais R, Vergnenegre A, Falchero L, Souquet PJ, Chavaillon JM, Taviot B, Fraboulet G, Saal H, Robert C, Chosidow O; CYTAR investigators. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. *J Am Acad Dermatol*. 2016 Jun;74(6):1077-85. doi: 10.1016/j.jaad.2016.01.019.
  39. Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). *Lung Cancer*. 2008 May;60(2):200-7. doi: 10.1016/j.lungcan.2007.10.003.
  40. Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. *Cancer Prev Res (Phila)*. 2009 May;2(5):440-9. doi: 10.1158/1940-6207.CAPR-08-0136.
  41. Garland LL, Guillen-Rodriguez J, Hsu CH, Yozwiak M, Zhang HH, Alberts DS, Davis LE, Szabo E, Merenstein C, Lel J, Zhang X, Liu H, Liu G, Spira AE, Beane JE, Wojtowicz M, Chow HS. Effect of Intermittent Versus Continuous Low-Dose Aspirin on Nasal Epithelium Gene Expression in Current Smokers: A Randomized, Double-Blinded Trial. *Cancer Prev Res (Phila)*. 2019 Nov;12(11):809-820. doi: 10.1158/1940-6207.CAPR-19-0036.
  42. Bonanni B, Serrano D, Maisonneuve P, Veronesi G, Johansson H, Aristarco V, Varricchio C, Cazzaniga M, Lazzeroni M, Rampinelli C, Bellomi M, Vecchi M, Spaggiari L, Vornik L, Brown PH, Beavers T, Guerrieri-Gonzaga A, Szabo E. Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial. *JNCI Cancer Spectr*. 2020 Oct 20;4(6):pkaa096. doi: 10.1093/jncics/pkaa096.
  43. Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F; GECO investigators. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. *Lancet Oncol*. 2007 Jun;8(6):500-12. doi: 10.1016/S1470-2045(07)70146-8.

44. Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE; Alliance for Clinical Trials in Oncology. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). *J Clin Oncol*. 2017 Jul 1;35(19):2184-2192. doi: 10.1200/JCO.2016.71.3743.
45. Koch A, Bergman B, Holmberg E, Sederholm C, Ek L, Kosieradzki J, Lamberg K, Thaning L, Ydreborg SO, Sörenson S; Swedish Lung Cancer Study Group. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. *Eur J Cancer*. 2011 Jul;47(10):1546-55. doi: 10.1016/j.ejca.2011.03.035.
46. Gitlitz BJ, Bernstein E, Santos ES, Otterson GA, Milne G, Syto M, Burrows F, Zaknoen S. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. *J Thorac Oncol*. 2014 Apr;9(4):577-82. doi: 10.1097/JTO.0000000000000082.
47. Regimen for the Treatment of Cachexia in Subjects With NSCLC (VT-122). (NCT00527319), ClinicalTrials.gov; January 30, 2013, <https://classic.clinicaltrials.gov/ct2/show/study/NCT00527319?term=NCT00527319&draw=2&rank=1> (accessed on October 28, 2023)
48. Li L, Jiang L, Wang Y, Zhao Y, Zhang XJ, Wu G, Zhou X, Sun J, Bai J, Ren B, Tian K, Xu Z, Xiao HL, Zhou Q, Han R, Chen H, Wang H, Yang Z, Gao C, Cai S, He Y. Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. *Clin Cancer Res*. 2019 Dec 1;25(23):6967-6975. doi: 10.1158/1078-0432.CCR-19-0437.
49. Keith RL, Blatchford PJ, Merrick DT, Bunn PA Jr, Bagwell B, Dwyer-Nield LD, Jackson MK, Geraci MW, Miller YE. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers. *Cancer Prev Res (Phila)*. 2019 Oct;12(10):721-730. doi: 10.1158/1940-6207.CAPR-19-0006.
50. Crandall C. Risedronate: a clinical review. *Arch Intern Med*. 2001 Feb 12;161(3):353-60. doi: 10.1001/archinte.161.3.353.
51. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol*. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304.
52. Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Ts

- ourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMG EN-249 trials. *Lung Cancer*. 2021 Nov;161:76-85. doi: 10.1016/j.lungcan.2021.09.002.
53. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. *Cancer*. 2004 Jun 15;100(12):2613-21. doi: 10.1002/cncr.20308.
54. Prophylactic Risedronate for Patients with Peripheral Lung Tumors Treated With SBRT. (NC T03861091), *ClinicalTrials.gov*; July 27, 2023, <https://classic.clinicaltrials.gov/ct2/show/NC/T03861091?term=NCT03861091&draw=1&rank=1> (accessed on October 28, 2023)
55. Scagliotti GV, Kosmidis P, de Marinis F, Schreurs AJM, Albert I, Engel-Riedel W, Schallier D, Barbera S, Kuo HP, Sallo V, Perez JR, Manegold C. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study. *Ann Oncol*. 2012 Aug;23(8):2082-2087. doi: 10.1093/annonc/mds128.
56. Kannappan V, Ali M, Small B, Rajendran G, Elzhenni S, Taj H, Wang W and Dou QP (2021) Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents. *Front. Mol. Biosci.* 8:741316. doi: 10.3389/fmolb.2021.741316
57. Liu, P., Wang, Z., Brown, S., Kannappan, V., Tawari, P. E., Jiang, W., et al. (2014). Liposome Encapsulated Disulfiram Inhibits NFκB Pathway and Targets Breast Cancer Stem Cells In Vitro and In Vivo. *Oncotarget* 5, 7471–7485. doi:10.18632/oncotarget.2166
58. Nechushtan H, Hamamreh Y, Nidal S, Gotfried M, Baron A, Shalev YI, Nisman B, Peretz T, Peylan-Ramu N. A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. *Oncologist*. 2015 Apr;20(4):366-7. doi: 10.1634/theoncologist.2014-0424.
59. Wu F, Lin X, Yang Z, Sun Z, Zeng F, Heng J, Qu J, Zeng L, Yang N, Zhang Y. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer. *Clin Lung Cancer*. 2018 Nov;19(6):e913-e918. doi: 10.1016/j.clcc.2018.08.006.
60. Carta JP, Guerra CE, Chang GJ, Gottumukkala V, Joshi GP. Non-steroidal anti-inflammatory drugs in the oncological surgical population: beneficial or harmful? A systematic review of the literature. *Br J Anaesth*. 2017 Oct 1;119(4):750-764. doi: 10.1093/bja/aez225.
61. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies. *Br J Cancer*. 2011 Jul 26;105(3):452-9. doi: 10.1038/bjc.2011.252.

62. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ*. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086.
63. Denisov EV, Schegoleva AA, Gervas PA, Ponomaryova AA, Tashireva LA, Boyarko VV, Bukreeva EB, Pankova OV, Perelmuter VM. Premalignant lesions of squamous cell carcinoma of the lung: The molecular make-up and factors affecting their progression. *Lung Cancer*. 2019 Sep;135:21-28. doi: 10.1016/j.lungcan.2019.07.001.
64. Ioakeim-Skoufa I, Tobajas-Ramos N, Menditto E, Aza-Pascual-Salcedo M, Gimeno-Miguel A, Orlando V, González-Rubio F, Fanlo-Villacampa A, Lasala-Aza C, Ostasz E, Vicente-Romero J. Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials. *Cancers (Basel)*. 2023 May 30;15(11):2972. doi: 10.3390/cancers15112972.
65. Dinić J, Efferth T, García-Sosa AT, Grahovac J, Padrón JM, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Repurposing old drugs to fight multidrug resistant cancers. *Drug Resist Updat*. 2020 Sep;52:100713. doi: 10.1016/j.drug.2020.100713.
66. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? *Acta Pharm Sin B*. 2022 Jul;12(7):3049-3062. doi: 10.1016/j.apsb.2022.02.002.
67. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. *Front Oncol*. 2021 Nov 23;11:778858. doi: 10.3389/fonc.2021.778858.
68. Rengan R, Mick R, Pryma DA, Lin LL, Christodouleas J, Plastaras JP, Simone CB 2nd, Gupta AK, Evans TL, Stevenson JP, Langer CJ, Kucharczuk J, Friedberg J, Lam S, Patsch D, Hahn SM, Maity A. Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial. *JAMA Oncol*. 2019 Oct 1;5(10):1464-1472. doi: 10.1001/jamaoncol.2019.2095.
69. Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. *Cancer Treat Rev*. 2017 Jan;52:12-21. doi: 10.1016/j.ctrv.2016.10.009.
70. Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: The changing landscape of the regulatory approval process. *Pharmacoepidemiol Drug Saf*. 2020 Oct;29(10):1201-1212. doi: 10.1002/pds.4932.
71. Gayen S. Malignant Pleural Effusion: Presentation, Diagnosis, and Management. *Am J Med*. 2022 Oct;135(10):1188-1192. doi: 10.1016/j.amjmed.2022.04.017.
72. Zhou T, Zhang Y, Ma Y, Ma W, Wu X, Huang L, Feng W, Zhou H, Liu J, Zhao H, Zhang L, Yang Y, Huang Y. Comparison of aprepitant versus desloratadine for EGFR-TKI-induced

pruritus: A randomized phase 2 clinical trial. *Cancer*. 2022 Nov 15;128(22):3969-3976. doi: 10.1002/cncr.34474.

73. Noronha V, Bhattacharjee A, Patil VM, Joshi A, Menon N, Shah S, Kannan S, Mukadam SA, Maske K, Ishi S, Prabhash K. Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial. *Chest*. 2020 Jun;157(6):1647-1655. doi: 10.1016/j.chest.2019.11.048.

### A) PubMed search

#### Exclusion criteria:

Aim is to obtain articles suggesting drug repurposing based on human clinical data.

1. Duplicates and non-English, inaccessible articles were excluded.
2. Articles on in-vitro and in-vivo models, in-silico studies, computational analysis, studies on COVID-19, pulmonary hypertension, asthma or fibrosis.
3. Any chemo drugs indicated or not for lung cancer were excluded.

#### Inclusion criteria:

Aim to obtain the non-chemo drug generic name.

1. Articles reporting or suggesting non-chemo drugs for lung cancer based on findings in human clinical trials were included.
2. Orphan drug or previously well-known non-chemo drug received approval for cancer post-registration of trial are included for further search.

### B) ClinicalTrials.gov search

Aim is to obtain the trial result.

#### Exclusion criteria:

1. All pre-clinical, review articles or articles published on similar non-chemo drug efficacy in cancer patients posted in trial registry, and phase-I study results were excluded
2. Other reasons includes non-lung cancer patients recruited in the studies, non-randomized study design, relevant trial registration number not found, meta-analysis were excluded.

#### Inclusion criteria:

1. Articles containing the trial registration number.
2. Randomized placebo-controlled trials were finally included.

### C) Google Scholar search

Aim is to obtain trial result

#### Exclusion criteria:


1. All review articles, phase-I and non-randomized studies were excluded.
2. Articles not containing trial registration number, pre-clinical studies, meta-analysis were excluded.

#### Inclusion criteria:

1. Articles containing trial registration number.
2. Randomized placebo-controlled trials were finally included.

**Figure 1:** Inclusion and exclusion criteria.





**Flow chart 1:** PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources.

<b>Drugs (Clinical Phase)</b>	<b>Trial identifier</b>	<b>Drugs</b>	<b>Clinical findings</b>	<b>Ref</b>
Disulfiram (phase-II)	NCT00312819	Cisplatin, vinorelbine plus placebo or disulfiram	Significantly higher PFS and OS in disulfiram group compared to chemo plus placebo group. Quality of life and response rate was not statistically significant.	59
Metformin (Phase-II)	NCT01864681	Gefitinib with placebo or metformin	No significant difference in ORR and PFS between the groups. Addition of metformin showed 22 months survival and higher incidence of diarrhea, compared to 27 months overall survival in gefitinib group with reduced diarrhea.	48
Minocycline (phase-II)	NCT00473083	Erlotinib with delayed or early minocycline treatment	Early minocycline exposure reduced severe incidence of rash compared to delayed exposure patients with no major difference in survival.	35
	NCT01636934	Post-chemo therapy with or no minocycline	Reduced grade 3 adverse events pain, fatigue, and shortness of breath in minocycline group compared to placebo.	36
Pravastatin (phase-III)	NCT00433498	Carboplatin, cisplatin, etoposide and/or pravastatin	No significant difference was found for pravastatin compared to placebo in SCLC subjects for OS, and PFS.	19
Aprepitant (phase-III)	NCT02161991	Palonosetron & Dexamethasone with or Without Aprepitant.	Post chemo aprepitant exposure significantly reduced vomiting but not nausea compared to unexposed patients.	60
Aspirin (phase-III)	NCT02123849	Low dose intermittent Vs continuous aspirin exposure.	No significant difference in adverse events observed between groups. Continuous exposure showed smoking associated gene expression pattern.	41
	NCT02169271	Low dose aspirin or placebo	There was no significant negative change in the size of the tumors in patients of the treatment group compared to placebo.	42
Zoledronic acid (phase-III)	NCT00172042	Vit. D and calcium supplementation with or without zoledronic acid	PFS, OS, and bone metastasis along with renal adverse event were not significantly different among groups.	56
	NCT00264420	Zoledronic acid infusion or placebo in lung cancer patients.	Significantly reduced and delayed skeletal related events in patients treated with zoledronic acid, bone pain was observed in both groups.	54
Denosumab (phase-III)	NCT01951586 NCT02129699	Chemotherapy-denosumab and chemotherapy-alone	Denosumab group did not show significant increase in OS, PFS. In subgroup analysis denosumab performed better than chemo alone in squamous cell carcinoma patients.	53
Thalidomide (phase-III)	NCT00004859	Carboplatin, paclitaxel, radiation and/or thalidomide.	Inclusion of thalidomide severely affected OS and grade 3 adverse events.	30
	NCT00061919	Etoposide, carboplatin placebo or thalidomide	No difference in OS, and PFS. All severe and non-severe adverse events were more frequent in thalidomide group.	29
Rofecoxib (phase-III)	NCT00385606	Rofecoxib plus gemcitabine, and cisplatin	Rofecoxib did not prolong OS, but improved PFS, ORR, reduced adverse events mainly pain, and quality of life.	43
Celecoxib (phase-III)	NCT01041781	Carboplatin plus gemcitabine for squamous and carboplatin plus	No significant difference in OS, PFS treated Vs placebo among groups. Significant difference in OS and PFS was observed post separation of patients based on high	44

		pemetrexed for non-squamous NSCLC with celecoxib or placebo	prostaglandin E2 metabolite from baseline.	
	NCT00300729	Palliative chemotherapy with celecoxib or placebo	No significant difference in OS, quality of life and pain was observed in celecoxib group compared to placebo. Females were more benefited from celecoxib than males in terms of OS. Leukocytopenia was frequent in celecoxib patients.	45
Apricoxib (phase-II)	NCT00652340	Erlotinib with Apricoxib or alone with placebo	Time to disease progression was found increased in apricoxib patients <65 years old.	46
Carboxyaminoimidazole (Phase-III)	NCT00003869	Post chemotherapy carboxyaminoimidazole or placebo	No significant difference in OS or disease progression observed between groups. Significantly lesser adverse events in placebo.	39
Itraconazole (phase-III)	NCT03664115	Platinum-based chemo or with itraconazole	The ORR and PFS are significantly higher in itraconazole group compared to placebo but no difference in overall survival.	31
Risedronate (Phase II)	NCT03861091	Post SBRT risedronate dosing	Reduced bone loss in lung cancer patients compare to placebo. No serious adverse event occurred in patients of treatment group.	54
Retinoic acid (Phase II)	NCT00002586	13 cis retinoic acid with or without tocopherol	No significant change observed in positive histological changes compared to placebo patients.	40
Etodolac plus propranolol (VT-122) (phase II)	NCT00527319	Post-surgery VT-122 or placebo	Post 1 month of therapy no major change in body mass or griping strength, 25% severe adverse events seen in treatment groups.	18
Simvastatin (Phase-II)	NCT00452244	Gefitinib alone or with simvastatin	Significant statistical difference seen in ORR, PFS. The OS was 13.5 months and 12 months in gefitinib plus simvastatin and gefitinib placebo groups, respectively.	20
	NCT01156545	Afatinib alone or with simvastatin	The ORR, PFS and OS was not significantly higher in Afatinib plus simvastatin group. Skin rash was mostly seen in Afatinib group.	21
Pioglitazone and clarithromycin (Phase-II)	NCT02852083	Nivolumab plus treosulfan, pioglitazone, clarithromycin or nivolumab and placebo.	No statistical significance observed in PFS, ORR, OS, grade 3-5 adverse events was higher in nivolumab group.	28
Pioglitazone (Phase-II)	NCT00780234	Pioglitazone alone or placebo in former or current smokers with high-risk LC subjects.	Pioglitazone did not improve dysplasia in patients.	49
Nitroglycerine (Phase II)	NCT01171170	Carboplatin, bevacizumab, paclitaxel with or without nitroglycerine.	Nitroglycerine did not improve OS and PFS compared to placebo. Headache was most prominently observed in treated patients.	22
	NCT04338867	Nitroglycerine plus whole brain radiotherapy (WBRT) or WBRT alone.	Nitroglycerine arm had enhanced ORR, PFS but not OS compared to placebo arm.	23
Doxycycline (Phase-II)	NCT00531934	Erlotinib alone or doxycycline combined	Reduced severity of folliculitis in doxycycline arm compared to control group patients.	38
		Post-dacomitinib	Significantly reduced dermatological events and increased	

	NCT01465802	treatment, doxycycline, placebo.	quality of life in doxycycline treatment group compared to placebo.	37
--	-------------	----------------------------------	---	----

**Table 1:** Phase II/III trial with randomized double blinded placebo-controlled trials, or randomized double-blinded study findings of 30 studies on advanced non-small cell lung cancer patients treated with chemo, immunotherapy or radiotherapy with 23 non-chemo drugs from pivotal studies are presented. SBRT; Stereotactic Body Radiation Therapy, OS; Overall Survival, PFS; Progression Free Survival, ORR; Overall response rate, LC; Lung Cancer,